Fintel on MSN6h
Cantor Fitzgerald Initiates Coverage of Acrivon Therapeutics (ACRV) with Overweight RecommendationFintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...
Cantor Fitzgerald reiterated a Neutral rating on Intel Corporation (NASDAQ:INTC) with a consistent price target of $22.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback